The prognostic value of IPI in patients with primary breast lymphoma, a multicenter retrospective study

BACKGROUND: Due to the rarity of PBL and the lack of large-scale studies, the prognostic value of IPI in PBL was controversial. Especially in the rituximab era, the ability of IPI to stratify prognosis in patients receiving immunochemotherapy was severely reduced. Then revised IPI (R-IPI) and Nation...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Kexin, Zhao, Shuangtao, Shang, Qingyao, Qiao, Guangdong, Liu, Jiaxiang, Yang, Chenxuan, Wei, Ya, Li, Yalun, Ren, Fei, Xuan, Lixue, Wang, Xiang, Wang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664603/
https://www.ncbi.nlm.nih.gov/pubmed/36376836
http://dx.doi.org/10.1186/s12935-022-02772-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664603/
https://www.ncbi.nlm.nih.gov/pubmed/36376836
http://dx.doi.org/10.1186/s12935-022-02772-y

Ejemplares similares